Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing klebsiella pneumoniae with similar MICs

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 7, 2013, Pages 1616-1618

  Hagihara, Mao ^a,b   Crandon, Jared L ^a   Urban, Carl ^c   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b AICHI MEDICAL UNIVERSITY   (Japan)

^c NEW YORK HOSPITAL QUEENS   (United States)

Author keywords

Antimicrobial susceptibility profiles; Carbapenemases; Genotypes; Mechanism of carbapenem resistance

Indexed keywords

DORIPENEM; ERTAPENEM; PORIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; INOCULATION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; THIGH;

EID: 84879493222     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt056     Document Type: Article

References (14)

1. Hoban DJ, Bouchillon SK, Hawser SP et al. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. Diagn Microbiol Infect Dis 2010; 66: 78-86.
2. Lim KT, Yeo CC, Yasin RM et al. Characterization of multidrug-resistant and extended-spectrum β-lactamase-producing Klebsiella pneumoniae strains from Malaysian hospitals. J Med Microbiol 2009; 58: 1463-9.
3. Turner PJ. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 2008; 60: 185-92.
4. Marchaim D, Navon-Venezia S, Schwaber MJ et al. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008; 52: 1413-8.
5. Bradford PA, Urban C, Mariano N et al. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997; 41: 563-9.
6. Souli M, Galani I, Antoniadou A et al. An outbreak of infection due to β-lactamase Klebsiella pneumoniae carbapenemase 2-producing Klebsiella pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010; 50: 364-73.
7. Urban C, Bradford PA, Tuckman M et al. Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase β-lactamases associated with long-term care facilities. Clin Infect Dis 2008; 46: e127-30.
8. Roth AL, Kurpiel PM, Lister PD et al. blaKPC RNA expression correlates with two transcriptional start sites but not always with gene copy number in four genera of Gram-negative pathogens. Antimicrob Agents Chemother 2011; 55: 3936-8.
9. Bulik CC, Nicolau DP. In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemaseproducing Klebsiella pneumoniae. Antimicrob Agents Chemother 2010; 54: 4112-5.
10. Bulik CC, Christensen H, Li P et al. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2010; 54: 804-10.
11. Urban C, Mariano N, Rahal JJ. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrugesistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 2010; 54: 2732-4.
12. Crandon JL, Bulik CC,NicolauDP. In vivo efficacyof 1- and 2-gramhuman simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 4352-6.
13. DeRyke CA, Banevicius MA, Fan HW et al. Bactericidal activities of meropenem and ertapenem against extended-spectrum-blactamase- producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother 2007; 51: 1481-6.
14. Kim A, Banevicius MA, Nicolau DP. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother 2008; 52: 2497-502.